NCT06518551 Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
| NCT ID | NCT06518551 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Omar Nadeem, MD |
| Condition | Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 49 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2029-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Eligibility Criteria
Inclusion Criteria: * Previously diagnosed with MM based on standard IMWG criteria * Patient has given voluntary written informed consent before any study-related procedures not part of normal medical care are performed, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. * Patient who has been treated with at least 4 prior lines of anti-myeloma treatment including immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. * In addition, to at least 4 prior lines of anti-myeloma treatment, patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) * Screening Laboratory evaluations within the following parameters * Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used more